Faster, more reliable cancer biomarker tests
Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies
This project creates new statistical tools to speed up and improve cancer biomarker tests used to detect cancer or guide treatment for people at risk or living with cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11233155 on NIH RePORTER |
What this research studies
Researchers at Fred Hutch are building new statistical methods to make phase III and IV cancer biomarker studies faster, cheaper, and more informative for patients. They will design ways to choose trial endpoints and account for overdiagnosis in screening trials, combine samples from different trial phases, and merge data from diverse patient groups and screening methods. The work focuses on using stored patient samples and real trial data to get better estimates of how tests perform in the real world. The goal is to get reliable biomarker tests to patients sooner while reducing wasted tests and trial costs.
Who could benefit from this research
Good fit: People who take part in cancer screening or biomarker validation trials, or who have donated samples to those studies, are the most likely to be involved or benefit.
Not a fit: Patients whose cancers or tests are not included in these biomarker projects or who do not participate in screening programs may not see direct benefits.
Why it matters
Potential benefit: If successful, patients could get access to accurate biomarker tests sooner, leading to earlier detection, better treatment choices, and fewer unnecessary procedures.
How similar studies have performed: Related statistical and trial-design advances have helped other medical tests move faster, but applying these specific methods to phase III/IV cancer biomarker validation is relatively new.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Huang, Ying — Fred Hutchinson Cancer Center
- Study coordinator: Huang, Ying
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.